This study shows that orally administered CF101, an A3AR agonist, possesses anticancer activity against HCT-116 human and CT-26 murine colon carcinoma, while having the ability to protect against chemotherapy-induced myelotoxicity. Here, ADORA3 is linked to colon carcinoma.